<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45183">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01856426</url>
  </required_header>
  <id_info>
    <org_study_id>CEDP239X2201</org_study_id>
    <nct_id>NCT01856426</nct_id>
  </id_info>
  <brief_title>Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects</brief_title>
  <official_title>Double-Blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of Single Doses of EDP239 in Hepatitis C Virus (HCV) Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is, to assess whether EDP239 can reduce the HCV viral load in HCV
      gentotype-1 in chronically infected subjects and to further evaluate the safety profile of
      EDP239.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline Hepatitis C viral load at Day 1</measure>
    <time_frame>baseline, day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood will be collected for Hepatitis C viral load at Day 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Laboratory and clinical evaluations will be used as safety events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HCV RNA log</measure>
    <time_frame>baseline, Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>A viral load drop in excess of 2.5 will be considered a success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total concentration in plasma of EDP239 in HCV Gentoype 1 infected subjects</measure>
    <time_frame>baseline, day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>The concentration in plasma parameters of EDP239 will be determined using the actual recorded sampling times and non-compartmental method.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>1- EDP239</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP239 given once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 treatment arm will be placebo, dose given once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2- EDP239</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP239 given once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3-EDP239</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP239 given once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4-EDP239</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP239 given once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP239</intervention_name>
    <arm_group_label>1- EDP239</arm_group_label>
    <arm_group_label>2- EDP239</arm_group_label>
    <arm_group_label>3-EDP239</arm_group_label>
    <arm_group_label>4-EDP239</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have chronic genotype-1 hepatitis C virus infection and plasma HCV-RNA
             ≥ 105 IU/mL at the time of screening.

          -  Subjects must have chronic HCV infection as determined by any of the following:

          -  be anti-HCV (+) for at least 6 months per subject history or medical records

          -  an anti-HCV test, viral load,  or genotype &gt; 6 months ago

          -  In the setting of a recent positive anti-HCV test (&lt; 6 months), liver biopsy
             demonstrating chronicity

          -  Subjects must have IL-28b genotype &quot;CC&quot;

          -  Subjects must weigh at least 50 kg to participate in the study, and must have a body
             mass index (BMI) within the range of 18 - 36 kg/m2. BMI = Body weight (kg) / [Height
             (m)]2

        Exclusion Criteria:

          -  Use of other investigational drugs at the time of enrollment, or within 5 half-lives
             of enrollment, or within 30 days (for small molecules) whichever is longer; or longer
             if required by local regulations.

          -  Previous treatment, including the use of any investigational agents, for the
             treatment of HCV infection.

          -  Women of child bearing potential.

          -  Subjects with IL-28b genotype &quot;CT or TT&quot;.

          -  ALT γ-GT, and AST must be below 5 x the upper limit of normal (ULN).

          -  Serum bilirubin must not exceed ULN.

          -  The PT (INR) must be within normal limits.

          -  If necessary, laboratory testing may be repeated on one occasion (as soon as
             possible) prior to randomization, to rule out any laboratory error.

          -  Use of drugs that inhibit or induce CYP3A4.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 12, 2013</lastchanged_date>
  <firstreceived_date>May 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C infected subjects</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
